Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ILK | Q13418 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376273 | 0.89 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL211851 | 0.86 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL4386068 | 0.81 | TLR7 (0.51) | TLR7ALDH1A1 | |
| SCHEMBL4383648 | 0.79 | PRMT5 (0.38) | TLR7TLR8 | |
| SCHEMBL5731728 | 0.74 | TLR7 (0.52) | TLR7SRCALDH1A1PKMCHRNB2 | |
| SCHEMBL211352 | 0.74 | TLR7 (0.71) | TLR7TLR8 | |
| SCHEMBL4385238 | 0.73 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL212611 | 0.72 | TLR7 (0.51) | TLR7SRCTLR8ALDH1A1 | |
| SCHEMBL4377041 | 0.71 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL4472369 | 0.71 | TLR7 (0.57) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329721-B2 | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20090298821-A1 | HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS | PFIZER INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2007106854-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZONAPHTHYRIDINES AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298821-A1 | HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS | IL2, IL4, IFNG | TLR7 61/4885SRC 1776/4885TLR8 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.